To include your compound in the COVID-19 Resource Center, submit it here.

KalVista leaps after Merck deal in DME

KalVista Pharmaceuticals Inc. (NASDAQ:KALV) shares jumped $2.79 (38%) to $10.17 on Tuesday after the company granted Merck

Read the full 174 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE